ArticleNature communications2024
Baseline levels and longitudinal changes in plasma Aβ42/40 among Black and white individuals.
Abstract readMulticenter Study
In one paragraph
Article in Nature communications, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed.
- Prognostic value of plasma brain-derived pTau.medRxiv : the preprint server for health sciences · 2026Article
- Longitudinal Change in CD86 Expression Is Associated with Regression of Cervical Intraepithelial Neoplasia.Biomedicines · 2026Article
- Differences in amyloid PET positivity based on ethnoracial group and social determinants of health: The new IDEAS study.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026Article
- Usage and positivity rates of Alzheimer's disease biomarkers in a memory clinic.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026Article
- Generalizability of blood-based biomarkers of Alzheimer's disease and related dementias in a multicultural cohort of older adults: The effect of adjustment for kidney function.Journal of Alzheimer's disease : JAD · 2026Article
- Association of plasma p-tau and p-tau/Aβ ratio with Alzheimer's pathology.The journal of prevention of Alzheimer's disease · 2026Article
- Blood-based biomarkers of Alzheimer's disease and neurodegeneration in an indigenous African cohort using both Simoa and NULISA platforms.NPJ dementia · 2026Article
- Fluid biomarkers for neurodegenerative diseases: a comprehensive update.Alzheimer's research & therapy · 2025Review
- Plasma growth-associated protein 43 correlates with synaptic loss in Alzheimer's disease.Cell reports. Medicine · 2025Article
- Assessing Cognitive Decline and Dementia Risk in Black and White Older Adults With Blood Biomarkers pTau217, GFAP, NfL, and Aβ Ratio.Neurology · 2025Article
- Blood-based Biomarkers of Alzheimer's Disease and Neurodegeneration in an Indigenous African Cohort using both SIMOA and NULISA Platforms.Research square · 2025Article
- Associations of Longitudinal Changes in Blood Biomarkers of Dementia With the Proportion of Genetically Inferred African Ancestry.Neurology · 2025Article
- Lifetime risk of incident dementia and incident mild cognitive impairment in older adults.medRxiv : the preprint server for health sciences · 2025Article
- Person-specific digital measurements of air pollutant exposure and biomarkers of Alzheimer's disease: Findings from a pilot study.Journal of Alzheimer's disease : JAD · 2025Article
- Novel set of plasma proteins classifies Alzheimer's dementia in African American individuals with high accuracy.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Article
- Neuroimaging and biofluid biomarkers across race and ethnicity in older adults across the spectrum of cognition.Ageing research reviews · 2024Review
- Linking evidence for targeted blood biomarkers in post-stroke cognitive impairment and dementia.Frontiers in stroke · 2024Review
- Population disparities in Alzheimer's disease: A systematic review of fluid and neuroimaging biomarkers.Alzheimer's & dementia (Amsterdam, Netherlands)Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
21 authors.
Chengjie Xiong *Division of Biostatistics, Washington University, St. Louis, MO, USA.
Jingqin Luo *Division of Public Health Sciences, Department of Surgery, Washington University School of Medicine, St. Louis, MO, USA.ORCID 0000-0003-2759-3072
David A WolkPerelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Leslie M ShawPerelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Erik D RobersonAlzheimer's Disease Center, Department of Neurology, University of Alabama at Birmingham, Birmingham, AL, USA.ORCID 0000-0002-1810-9763
Charles F MurchisonAlzheimer's Disease Center, Department of Neurology, University of Alabama at Birmingham, Birmingham, AL, USA.
Rachel L HensonDepartment of Neurology, Washington University School of Medicine, St. Louis, MO, USA.
Tammie L S BenzingerDepartment of Neurology, Washington University School of Medicine, St. Louis, MO, USA.ORCID 0000-0002-8114-0552
Quoc BuiDivision of Biostatistics, Washington University, St. Louis, MO, USA.
Folasade AgboolaDivision of Biostatistics, Washington University, St. Louis, MO, USA.
Elizabeth GrantDivision of Biostatistics, Washington University, St. Louis, MO, USA.
Emily N GremmingerDivision of Biostatistics, Washington University, St. Louis, MO, USA.
Krista L MoulderDepartment of Neurology, Washington University School of Medicine, St. Louis, MO, USA.
David S GeldmacherAlzheimer's Disease Center, Department of Neurology, University of Alabama at Birmingham, Birmingham, AL, USA.
Olivio J ClayAlzheimer's Disease Center, Department of Neurology, University of Alabama at Birmingham, Birmingham, AL, USA.
Ganesh BabulalDepartment of Neurology, Washington University School of Medicine, St. Louis, MO, USA.
Carlos CruchagaDepartment of Neurology, Washington University School of Medicine, St. Louis, MO, USA.ORCID 0000-0002-0276-2899
David M HoltzmanDepartment of Neurology, Washington University School of Medicine, St. Louis, MO, USA.ORCID 0000-0002-3400-0856
Randall J BatemanDepartment of Neurology, Washington University School of Medicine, St. Louis, MO, USA.ORCID 0000-0002-7729-1702
John C MorrisDepartment of Neurology, Washington University School of Medicine, St. Louis, MO, USA.
Suzanne E SchindlerDepartment of Neurology, Washington University School of Medicine, St. Louis, MO, USA. schindler.s.e@wustl.edu.ORCID 0000-0002-1680-1465
Funding
Smartphone-Based "Burst" Cognitive AssessmentsP01AG003991 · NIA · WASHINGTON UNIVERSITY · PI JOHN MORRIS · 1985 to 2026
$69.5MThe natural history of AB accumulation in preclinical ADP01AG026276 · NIA · WASHINGTON UNIVERSITY · PI MORRIS, JOHN · 2005 to 2025
$49.5MResearch Education ComponentP30AG066444 · NIA · WASHINGTON UNIVERSITY · PI Susan Lynn Stark · 2020 to 2026
$28.7MResearch Education ComponentP30AG072979 · NIA · UNIVERSITY OF PENNSYLVANIA · PI DAVID A WOLK · 2021 to 2026
$24.8MCross Sectional and Longitudinal Racial Disparity in Molecular Biomarkers of Alzheimer DiseaseR01AG067505 · NIA · WASHINGTON UNIVERSITY · PI XIONG, CHENGJIE · 2020 to 2024
$14.7MStaging Alzheimer disease with blood-based biomarkersR01AG070941 · NIA · WASHINGTON UNIVERSITY · PI SCHINDLER, SUZANNE ELIZABETH · 2021 to 2025
$4.3MUAB Alzheimer's Disease Research CenterP20AG068024 · NIA · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI CLAY, OLIVIO J · 2020 to 2022
$3.3MPlasma Abeta isoform concentrations in cognitively impaired patients at risk for amyloidosisR44AG059489 · NIA · C2N DIAGNOSTICS, LLC · PI WEST, TIM · 2018 to 2020
$2.0MNIA NIH HHS P01 AG003991NIA NIH HHS P01 AG026276NIA NIH HHS P20 AG068024NIA NIH HHS P30 AG066444NIA NIH HHS P30 AG072979NIA NIH HHS R01 AG067505NIA NIH HHS R01 AG070941NIA NIH HHS R44 AG059489
Abstract
Blood-based biomarkers of Alzheimer disease (AD) may facilitate testing of historically under-represented groups. The Study of Race to Understand Alzheimer Biomarkers (SORTOUT-AB) is a multi-center longitudinal study to compare AD biomarkers in participants who identify their race as either Black or white. Plasma samples from 324 Black and 1,547 white participants underwent analysis with C
Indexed as
Alzheimer DiseaseAmyloid beta-PeptidesBiomarkersPeptide FragmentsWhite PeopleAgedAged, 80 and overBlack or African AmericanBlack PeopleFemaleHumansLongitudinal StudiesMaleMiddle AgedAmyloid beta-Peptidesamyloid beta-protein (1-40)amyloid beta-protein (1-42)BiomarkersPeptide Fragments
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.